Webinar Overview
Alzheimer’s disease (AD) is the most common type of dementia, and is a multifactorial neurodegenerative disease. While protein pathology related to beta-amyloid plaques and neurofibrillary tau deposits are observed in AD, early molecular alterations are not very clear yet, especially pathology related to the dysfunction of glymphatic clearance.
Kannie Chan discusses, how she and her team demonstrated that CEST MRI could identify an obvious decrease in CSF clearance at early stage of AD in a mouse model. Moreover, altered glucose uptake and kinetics in both CSF and parenchyma were detected. These alterations in multiple CEST parameters were not observed in normal age-matched mice. Together with deep-learning assisted CEST assessment of protein alterations, CEST MRI could provide additional multi-parametric assessments of AD pathology non-invasively.
On Demand Session
Speaker
Prof. Kannie Chan
Associate Professor of Biomedical Engineering at City University of Hong Kong, Hong Kong
and Adjunct Faculty at Johns Hopkins University, Baltimore, MD, USAProf. Kannie Chan is an Associate Professor of Biomedical Engineering at City University of Hong Kong and an Adjunct Faculty at Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University. Her research focuses on the development of biomaterials and imaging approaches to facilitate clinical translations of cancer therapy and cell therapy, and early diagnosis of neurodegenerative diseases. She developed imaging of glucose using CEST-MRI, which has many implications in diseases in the brain, such as Alzheimer’s disease.